Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China - Poll - MDSpire

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • By

  • Honghong Yang

  • Qing Yu

  • Mei Li

  • Min Liu

  • June 9, 2026

  • 0 min

Share

Original Source(s)

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • by Honghong Yang, Qing Yu, Mei Li, Min Liu

  • June 9, 2026

Related Content

De novo NFKBIA variants within the N-terminal hotspot: consistent immunophenotype and divergent clinical presentations

Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"